Agreement between pharmaceutical claims data and patient-reported medication use after stroke

Int J Pharm Pract. 2021 Aug 11;29(4):397-399. doi: 10.1093/ijpp/riab032.

Abstract

Objectives: To assess the agreement between pharmaceutical claims data and patient-reported medication use after stroke.

Methods: Claims data from the Pharmaceutical Benefits Scheme were used to estimate medication use for a subset of participants registered in the Australian Stroke Clinical Registry in 2016. Estimates on medication use were validated against patient-reported responses (considered the reference standard).

Key findings: For antihypertensive and lipid-lowering medications, the sensitivity of claims data was excellent (85-87%) and the specificity was good (73-78%). Whereas for antithrombotic medications, sensitivity was modest (61%), but specificity was excellent (85%).

Conclusions: Pharmaceutical claims data can be used to infer medication use after stroke with mostly good to excellent sensitivity and specificity compared with the patient report.

Keywords: administrative claims; healthcare validation study; pharmacoepidemiology; registries; stroke.

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Australia
  • Humans
  • Patient Reported Outcome Measures
  • Pharmaceutical Preparations*
  • Stroke* / drug therapy

Substances

  • Antihypertensive Agents
  • Pharmaceutical Preparations